Vonoprazan Can Be Used with Aspirin and Atorvastatin, But Use Caution with Clopidogrel
Vonoprazan is safe to co-administer with aspirin and atorvastatin based on FDA drug interaction data, but it significantly attenuates the antiplatelet effect of clopidogrel and should be avoided or used with heightened monitoring when clopidogrel is essential.
Key Drug Interactions
Vonoprazan + Aspirin: Safe
The FDA label explicitly states that co-administration of vonoprazan 40 mg with aspirin 100 mg showed no clinically meaningful changes in exposure of either drug 1. This is further supported by a pharmacokinetic study demonstrating no interaction between vonoprazan and low-dose aspirin 2.
Vonoprazan + Atorvastatin: Use with Monitoring
Vonoprazan increases atorvastatin exposure by approximately 93% when co-administered 1. A dedicated drug interaction study confirmed that vonoprazan significantly increased systemic exposure of atorvastatin and atorvastatin lactone, while decreasing the metabolic ratio of the active metabolite 2-hydroxyatorvastatin 3. This interaction also led to hypergastrinemia in the vonoprazan group.
Clinical approach: This combination can be used, but consider:
- Starting with lower atorvastatin doses or monitoring for statin-related adverse effects (myalgias, elevated liver enzymes)
- The AHA guideline notes that atorvastatin with calcium channel blockers shows only minor increases in exposure and is reasonable 4
- The increased atorvastatin exposure with vonoprazan is comparable to moderate drug interactions that are clinically manageable
Vonoprazan + Clopidogrel: Significant Concern
This is the most problematic combination. Vonoprazan attenuates clopidogrel's antiplatelet effect more potently than traditional PPIs like esomeprazole. A study using P2Y12 assays demonstrated that vonoprazan decreased platelet inhibition significantly more than esomeprazole for both clopidogrel (P<0.001) and prasugrel (P=0.011), across all CYP2C19 genotype groups 5.
The mechanism involves:
- Vonoprazan inhibits CYP2C19, CYP2B6, and CYP3A4/5 1
- Clopidogrel requires CYP2C19 and CYP3A4 for conversion to its active metabolite 6
- This creates a clinically significant drug-drug interaction reducing clopidogrel efficacy
Critical context from guidelines: The 2010 ACCF/ACG/AHA consensus warns that PPIs (particularly omeprazole) reduce clopidogrel's antiplatelet effects, though the clinical significance remains debated 7. The FDA clopidogrel label specifically states to avoid concomitant use with omeprazole or esomeprazole 6. Since vonoprazan shows even stronger interaction than traditional PPIs, this concern is amplified.
Clinical Algorithm for Decision-Making
If the patient requires clopidogrel for high-risk cardiovascular indications (recent ACS, coronary stent):
Avoid vonoprazan - choose an alternative gastroprotective agent:
- H2 receptor antagonists (famotidine) have less interaction potential 7
- Consider non-CYP2C19 inhibiting PPIs, though all PPIs have some interaction
If vonoprazan is essential for GI protection:
- Consider switching from clopidogrel to prasugrel or ticagrelor (though vonoprazan also affects prasugrel to a lesser degree 5, 8)
- If clopidogrel must be continued, consider platelet function testing to assess adequate antiplatelet effect
- Balance the cardiovascular thrombotic risk against GI bleeding risk 7
For patients with lower cardiovascular risk (stable CAD on clopidogrel for secondary prevention):
- The interaction may be more acceptable if GI bleeding risk is high
- Close monitoring for cardiovascular events is warranted
If the patient is NOT on clopidogrel:
- Vonoprazan with aspirin alone is safe
- Vonoprazan with atorvastatin requires dose awareness but is manageable
Important Caveats
Atorvastatin-clopidogrel interaction: Some evidence suggests atorvastatin itself may reduce clopidogrel efficacy through CYP3A4 competition 9, though other studies show clinical benefit of the combination 10, 11. The addition of vonoprazan creates a "triple interaction" scenario that compounds the problem.
CYP2C19 poor metabolizers: Patients who are CYP2C19 poor metabolizers already have reduced clopidogrel efficacy 6. Adding vonoprazan in these patients essentially eliminates clopidogrel's benefit.
Prasugrel alternative: While one study showed vonoprazan had acceptable platelet reactivity with prasugrel in clinical practice 8, the P2Y12 assay data shows vonoprazan still significantly reduces prasugrel's effect 5.